A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

Breast Cancer Research and Treatment

Volumn 146, Issue 1, 2014, Pages 109-116

  Lintermans, A ^a   Van Asten, K ^a   Wildiers, H ^a,b   Laenen, A ^a   Paridaens, R ^a,b   Weltens, C ^b   Verhaeghe, J ^a,b   Vanderschueren, D ^a,b   Smeets, A ^a,b   Van Limbergen, E ^b   Leunen, K ^a,b   Christiaens, M R ^a,b   Neven, P ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aromatase inhibitor; Arthralgia; BMI; Breast cancer; Grip strength; Tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; VISUAL ANALOG SCALE; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; COMPLICATION; HAND STRENGTH; MEDICATION COMPLIANCE; METASTASIS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; MUSCULOSKELETAL PAIN; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HAND STRENGTH; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; MUSCULOSKELETAL PAIN; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TAMOXIFEN;

EID: 84903719065     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2986-7     Document Type: Article

References (30)

1. Petit T, Dufour P, Tannock I (2011) A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocr Relat Cancer 18(3):R79-R89
2. Thürlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Rabaglio M et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747-2757 (Pubitemid 43016814)
3. Crew K, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman D (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877-3883 (Pubitemid 47477264)
4. Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365-372
5. Coleman R, Bolten W, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275-282
6. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens M et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147-3152
7. Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis generating findings for its pathogenesis. Ann Oncol 22(8):1763-1769
8. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, members P (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206-2223
9. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97-102 (Pubitemid 41399883)
10. von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 13:426
11. Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC (2013) Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors. Oncol Nurs Forum 40(6):549-557
12. Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 64(12):1910-1918
13. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624-1632
14. Irwin ML, Cartmel B, Gross C (2013) Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: the hormones and physical exercise (HOPE) study. In: San Antonio Breast Cancer Symposium: 2013, San Antonio, 2013
15. Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Fabian CJ (2012) Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: the VITAL trial. In: ASCO: 2012, Chicago, 2012
16. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117(24):5469-5475
17. Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50(2):267-276
18. Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL (2013) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer 21(4):1077-1087
19. Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M (2012) Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32(6):2331-2336
20. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936-942
21. Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS (2013) Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 14(3):290-296
22. Park JY, Lee SK, Bae SY, Kim J, Kim MK, Kil WH, Lee JE, Nam SJ (2013) Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc 85(5):205-211
23. Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ (2013) Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401
24. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes J, Bianco A, Buzdar A, Group AT (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866-872
25. Hirokaga K, Egawa C, Takao S (2013) Chemotherapy, but not body mass index has impact on joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. In: San Antonio Breast Cancer Symposium: 2013, San Antonio, 2013
26. Muslimani A, Spiro T, Chaudhry A, Taylor H, Jaiyesimi I, Daw H (2009) Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9(1):34-38
27. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631-3639
28. Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, Tangoku A, Sasa M (2011) The time since last menstrual period is important as a clinical predictor for nonsteroidal aromatase inhibitor-related arthralgia. BMC Cancer 11:436
29. Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P et al (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain 15(3):293-303
30. Chlebowski RT, Kim JS, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 7(4):378-387